Drugmaker To Pay $4M To End Claims It Dodged FDA Fees
A Pennsylvania drugmaker has agreed to pay $4 million to end False Claims Act allegations it tried to circumvent U.S. Food and Drug Administration fees by paying companies eligible for fee...To view the full article, register now.
Already a subscriber? Click here to view full article